Published in Telemedicine Law Weekly, July 31st, 2004
Results of these studies demonstrated that ACP-103, Acadia's proprietary 5-HT2A inverse agonist, was safe and well tolerated in Parkinson disease patients at drug plasma levels many fold higher than those required for maximal brain occupancy of the 5-HT2A receptors, suggesting a large therapeutic index.
ACP-103 was discovered by scientists at Acadia...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Telemedicine Law Weekly